Mitomycin-C nephrotoxicity: a clinico-pathologic study of 17 cases.
The potential nephrotoxicity of Mitomycin-C (MMC) was studied in 17 autopsies from patients treated with this drug, usually in association with other anti-neoplastic agents. Renal functional deterioration was present in seven cases while urinalysis showed an overt proteinuria and hematuria in six and four instances, respectively. Four of these patients also developed a severe microangiopathic hemolytic anemia (MAHA) and thrombopenia. Histological examination did not reveal residual tumor in three of them. However renal lesions similar to those observed in the hemolytic-uremic syndrome (HUS) were associated with glomerular mesangiolytic changes and nuclear atypias in glomerular and tubular cells. Immunofluorescence and ultrastructural studies confirmed these findings. In other patients, variable degrees of cellular atypias and of mesangiolysis were observed. The severity of the glomerular, vascular, and tubular lesions correlated with the total dosage of MMC received. The nephrotoxic potential of MMC seems to be delayed in onset and dose related.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D002196:Capillaries / Q000187:drug effects / Q000473:pathology; D005260:Female; D005920:Glomerular Mesangium / Q000098:blood supply / Q000473:pathology; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects*
D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D016685:Mitomycin